1.	Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Phase: Phase IV Type: Supportive care, Treatment Status: Completed Age: Over 18 Sponsor: Other Protocol IDs: CDR0000257189, AGOSG-OVAR-MO16375-MARCH, EU-20217, ROCHE-MO16375, ROCHE-RO2053859, NCT00046969
2.	A Study of the Quality of Life and Treatment Response to Once Weekly NeoRecormon (Epoetin Beta) Treatment in Anemic Patients With Solid and Lymphoid Malignancies. Phase: Phase IV Type: Supportive care Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML20197, NCT00776425
3.	Phase III Randomized Study of Two Different Schedules of Docetaxel in Combination With Prednisone in Patients With Hormone-Refractory Metastatic Prostate Cancer Phase: Phase III Type: Treatment Status: Completed Age: Over 18 Sponsor: Other Protocol IDs: AVENTIS-FIN-1-2003, FINNISH-URO-OGS-1-2003, PROSTY-FIN-1-2003, ICORG-06-14-Prosty, EU-20891, NCT00255606
4.	Phase III Randomized Study of Recombinant Epoetin Alfa or Epoetin Beta With Versus Without Parenteral Iron in Anemic, Iron-Replete Patients With Nonmyeloid Malignancies Phase: Phase III Type: Supportive care Status: Closed Age: Over 16 Sponsor: Other Protocol IDs: BARTS-06/Q0605/93, ISRCTN11830961, EU-20731, 06/Q0605/93, NCT00482716
5.	Clinical Study of Epoetin Beta to Chemotherapy-Induced Anemia (CIA) Patients Phase: Phase III Type: Supportive care, Treatment Status: Completed Age: 20 to 79 Sponsor: Pharmaceutical / Industry Protocol IDs: EPO316 JP, NCT00628043
6.	Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 61 to 75 Sponsor: Other Protocol IDs: BACOPP-21, NCT00284271
7.	Epoetin Beta in Treating Fatigue and Anemia in Patients Receiving Palliative Care for Malignant Solid Tumors Phase: Phase II Type: Supportive care Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: CDR0000574173, CHUL-NEOPALIA, RECF0359, NEOPALIA, NCT00559195
8.	A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes. Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML20559, NCT00551291
9.	An Observational Study of Blood Management Techniques in Oncology Surgical Treatment Phase: No phase specified Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR003460, EPOSUR4001, NCT00264095